Drug Repurposing News and Research

RSS

Researchers use EHRs to uncover hidden drug benefits

With research and development costs for many drugs reaching well into the billions, pharmaceutical companies want more than ever to determine whether their drugs already at market have any hidden therapeutic benefits that could warrant putting additional indications on the label and increase production.

27 Nov 2014

Transparency Life receives SBIR program grant to fund Phase 2a proof-of-concept study for MS

Transparency Life Sciences, LLC (TLS), the world's first clinical-stage drug development company based on open innovation, today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).

8 Sep 2014

Research to identify cancer-busting 'genetic partners' can personalize cancer treatment

Despite the revolutionary biotechnological advancements of the last few decades, an ideal anti-cancer treatment - one that's immediately lethal to cancer cells, harmless to healthy cells, and resistant to cancer's relapse - is still a dream.

4 Sep 2014

New article describes about crowdsourcing and drug repurposing needs

Experimental drugs proven safe but perhaps not sufficiently effective in initial testing or against a first disease target may sit gathering dust on the shelves of pharmaceutical companies.

17 Jul 2014

New report reveals potential breakthrough in pterygium treatment

A new report reveals a potential breakthrough in the treatment of a common eye ailment known as pterygium (Surfer's eye) that impacts the vision, eye health, and cosmetic appearance of countless sufferers.

1 Apr 2014

Old FDA-approved drugs may hold promise for treatment of rare, drug-resistant cancer

University of Pittsburgh Cancer Institute (UPCI) scientists have shown that old drugs might be able to do new tricks.

14 Feb 2014

Myelin Repair Foundation enters into agreement with NIH to assess MRF-008 for multiple sclerosis

The Myelin Repair Foundation today announced it has entered a Cooperative Research and Development Agreement with the National Institutes of Health to assess MRF-008, as a potential therapeutic for multiple sclerosis. This CRADA will facilitate collaboration between the MRF and National Institute of Neurological Disorders and Stroke at the NIH Clinical Center to study MRF-008, a drug identified by the MRF as a potential neuroprotective therapeutic to enhance repair in multiple sclerosis patients.

27 Jan 2014

ADDF, Alzheimer's Society partner to provide funding for research in Alzheimer's disease

Today the Alzheimer's Drug Discovery Foundation and the Alzheimer's Society (UK) announced a new partnership that will provide funding for research in Alzheimer's disease and related dementias, with the goal of accelerating critical development programs and bringing new treatments to patients. The partnership intends to fund projects up to $1.5 million each focused on drug repurposing, leveraging existing scientific evidence and research to accelerate the drug development process.

24 Jan 2014

New Journal presents techniques for finding new uses for approved drugs

Mary Ann Liebert, Inc., publishers is pleased to announce Drug Repurposing, Rescue, and Repositioning, a dynamic new peer-reviewed journal that will present techniques and tools for finding new uses for approved drugs—particularly for disorders where no animal model, physiologic abnormality, biochemical pathway, or molecular target has been identified.

12 Dec 2013

Study finds persistent deficiency in new therapeutics for neglected diseases

In a study published today in the open-access journal The Lancet Global Health, the Drugs for Neglected Diseases initiative and other researchers report a persistent deficiency in truly new therapeutics for neglected diseases, despite nominal progress and an acceleration in research and development efforts. This continued 'fatal imbalance' in medical R&D points to the urgent need to develop and deliver groundbreaking new treatments for the world's poorest and most neglected patients.

25 Oct 2013

EMRs emerge as valuable resource for detecting bad drug reactions

NJIT Assistant Professor Mei Liu, PhD, a computer scientist, has recently shown in a new study that electronic medical records can validate previously reported adverse drug reactions and report new ones.

6 Jun 2013

Scientists demonstrate feasibility of using already-approved drugs against pathogens

In the most extensive screen of its kind, Texas Biomed scientists in San Antonio have demonstrated the feasibility of repurposing already-approved drugs for use against highly pathogenic bacteria and viruses.

11 Apr 2013

SOM Biotech closes first financing round and files patent application

SOM Biotech, a biopharmaceutical start-up company with a business model centered on the identification and development of drug repurposing opportunities, reports significant progress on its trajectory towards pipeline development and candidate outlicensing.

14 Mar 2011

Intellikine, PKD Foundation to investigate novel therapies for patients with PKD

Intellikine, a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, and the PKD Foundation today announced a collaboration to investigate novel, orally-available small molecule kinase inhibitors of the TORC1 and TORC2 complexes as a potential treatment for patients with polycystic kidney disease.

11 Feb 2011

Alte Biosciences files patent for novel inflammatory bowel disease drugs

Alte Bioscience, Inc., a development stage pharmaceutical company, is pleased to announce the filing of a provisional patent for a new class of drugs that may benefit patients with inflammatory bowel disease.

3 Sep 2008